Changes in Hong Kong stocks | Cornerstone Pharmaceutical-B (02616) rose more than 3% in early trading, Platinib capsules were included in the 2025 National Health Insurance Catalogue

The Zhitong Finance App learned that Cornerstone Pharmaceutical-B (02616) rose more than 3% in early trading. As of press release, it had risen 2.51% to HK$5.71, with a turnover of HK$7.294 million.

According to the news, on December 8, Cornerstone Pharmaceutical-B announced that the company Pujihua® (Platinib capsules, 100 mg) has been included in the latest “National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalogue” published by China's National Medical Security Administration. The catalogue will be officially implemented on January 1, 2026.

According to reports, Pujihua® was developed by Cornerstone Pharmaceutical's partner Blueprint Medicines (which was acquired by Sanofi in July 2025). Cornerstone Pharmaceuticals has exclusive development and commercialization rights for Pukehua® in the Greater China region (including mainland China, Hong Kong, Macau, and Taiwan). In November 2023, Cornerstone Pharmaceuticals granted exclusive commercialization promotion rights for Pujihua® in mainland China to Shanghai Alice Pharmaceutical Technology Co., Ltd.